Logo image of PRTA

PROTHENA CORP PLC (PRTA) Stock Fundamental Analysis

NASDAQ:PRTA - IE00B91XRN20 - Common Stock

8.56 USD
+0.21 (+2.51%)
Last: 8/27/2025, 8:12:46 PM
8.47 USD
-0.09 (-1.05%)
After Hours: 8/27/2025, 8:12:46 PM
Fundamental Rating

3

Taking everything into account, PRTA scores 3 out of 10 in our fundamental rating. PRTA was compared to 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRTA as it has an excellent financial health rating, but there are worries on the profitability. PRTA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRTA had negative earnings in the past year.
PRTA had a negative operating cash flow in the past year.
In the past 5 years PRTA reported 4 times negative net income.
PRTA had negative operating cash flow in 4 of the past 5 years.
PRTA Yearly Net Income VS EBIT VS OCF VS FCFPRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -75.91%, PRTA is doing worse than 65.27% of the companies in the same industry.
With a Return On Equity value of -93.40%, PRTA perfoms like the industry average, outperforming 47.17% of the companies in the same industry.
Industry RankSector Rank
ROA -75.91%
ROE -93.4%
ROIC N/A
ROA(3y)-19.63%
ROA(5y)-16.25%
ROE(3y)-23.37%
ROE(5y)-23.22%
ROIC(3y)N/A
ROIC(5y)N/A
PRTA Yearly ROA, ROE, ROICPRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRTA Yearly Profit, Operating, Gross MarginsPRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PRTA has been increased compared to 1 year ago.
Compared to 5 years ago, PRTA has more shares outstanding
PRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRTA Yearly Shares OutstandingPRTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRTA Yearly Total Debt VS Total AssetsPRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

PRTA has an Altman-Z score of -1.99. This is a bad value and indicates that PRTA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.99, PRTA perfoms like the industry average, outperforming 52.47% of the companies in the same industry.
There is no outstanding debt for PRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.99
ROIC/WACCN/A
WACC7.49%
PRTA Yearly LT Debt VS Equity VS FCFPRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

PRTA has a Current Ratio of 5.68. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.
PRTA has a better Current ratio (5.68) than 61.43% of its industry peers.
PRTA has a Quick Ratio of 5.68. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.
PRTA has a Quick ratio of 5.68. This is in the better half of the industry: PRTA outperforms 61.61% of its industry peers.
Industry RankSector Rank
Current Ratio 5.68
Quick Ratio 5.68
PRTA Yearly Current Assets VS Current LiabilitesPRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

PRTA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -403.00%.
The Revenue for PRTA has decreased by -95.24% in the past year. This is quite bad
PRTA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 178.96% yearly.
EPS 1Y (TTM)-403%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-241.8%
Revenue 1Y (TTM)-95.24%
Revenue growth 3Y-12.33%
Revenue growth 5Y178.96%
Sales Q2Q%-96.65%

3.2 Future

PRTA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.62% yearly.
PRTA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.38% yearly.
EPS Next Y-78.72%
EPS Next 2Y33.21%
EPS Next 3Y11.93%
EPS Next 5Y26.62%
Revenue Next Year-81.97%
Revenue Next 2Y-6.02%
Revenue Next 3Y-3.35%
Revenue Next 5Y25.38%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PRTA Yearly Revenue VS EstimatesPRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
PRTA Yearly EPS VS EstimatesPRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRTA. In the last year negative earnings were reported.
Also next year PRTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRTA Price Earnings VS Forward Price EarningsPRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRTA Per share dataPRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.21%
EPS Next 3Y11.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTHENA CORP PLC

NASDAQ:PRTA (8/27/2025, 8:12:46 PM)

After market: 8.47 -0.09 (-1.05%)

8.56

+0.21 (+2.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners74.37%
Inst Owner Change-20%
Ins Owners20.17%
Ins Owner Change45.8%
Market Cap460.78M
Analysts74.29
Price Target26.52 (209.81%)
Short Float %10.12%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.83%
Min EPS beat(2)-28.86%
Max EPS beat(2)-12.81%
EPS beat(4)1
Avg EPS beat(4)-8.72%
Min EPS beat(4)-28.86%
Max EPS beat(4)8.41%
EPS beat(8)3
Avg EPS beat(8)47.94%
EPS beat(12)5
Avg EPS beat(12)36.25%
EPS beat(16)5
Avg EPS beat(16)20.6%
Revenue beat(2)0
Avg Revenue beat(2)-37.48%
Min Revenue beat(2)-55.76%
Max Revenue beat(2)-19.2%
Revenue beat(4)0
Avg Revenue beat(4)-42.43%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)-19.2%
Revenue beat(8)2
Avg Revenue beat(8)106.61%
Revenue beat(12)3
Avg Revenue beat(12)61.95%
Revenue beat(16)3
Avg Revenue beat(16)29.55%
PT rev (1m)7.06%
PT rev (3m)-49.76%
EPS NQ rev (1m)20.43%
EPS NQ rev (3m)14.33%
EPS NY rev (1m)-2.17%
EPS NY rev (3m)-11.29%
Revenue NQ rev (1m)23.78%
Revenue NQ rev (3m)-51.03%
Revenue NY rev (1m)-23.29%
Revenue NY rev (3m)-50.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 44.56
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.42
EV/EBITDA N/A
EPS(TTM)-5.03
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-3.58
FCFYN/A
OCF(TTM)-3.58
OCFYN/A
SpS0.19
BVpS6.03
TBVpS6.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.91%
ROE -93.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.63%
ROA(5y)-16.25%
ROE(3y)-23.37%
ROE(5y)-23.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.11%
Cap/Sales 1.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.68
Quick Ratio 5.68
Altman-Z -1.99
F-Score2
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)132.78%
Cap/Depr(5y)92.67%
Cap/Sales(3y)1.38%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-403%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-241.8%
EPS Next Y-78.72%
EPS Next 2Y33.21%
EPS Next 3Y11.93%
EPS Next 5Y26.62%
Revenue 1Y (TTM)-95.24%
Revenue growth 3Y-12.33%
Revenue growth 5Y178.96%
Sales Q2Q%-96.65%
Revenue Next Year-81.97%
Revenue Next 2Y-6.02%
Revenue Next 3Y-3.35%
Revenue Next 5Y25.38%
EBIT growth 1Y-172.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.93%
OCF growth 3YN/A
OCF growth 5YN/A